01 Sep Finerenone Reduces Urine Protein Loss in Diabetic Kidney Disease

MedicalResearch.com Interview with:
George L. Bakris MD
Professor of Medicine
Director, Comprehensive Hypertension Center
University of Chicago Medicine

Medical Research: What is the background for this study? What are the main findings?

Dr. Bakris: Aldosterone receptor antagonists such as spironolactone are known to reduce mortality from heart failure and reduce albuminuria, a well-known marker of diabetic kidney disease progression. Finerenone is a novel nonsteroidal aldosterone receptor antagonist and is associated with less hyperkalemia (high blood potassium levels) compared to traditional aldosterone receptor blockers like spironolactone. The current study was a dose finding study to ascertain the optimal dose of finerenone for reducing urine albumin (a key risk marker in people with diabetic kidney disease) that is also associated with the smallest rise in serum potassium. The main findings are that in a dose dependent manner finerenone reduced albuminuria and at the highest dose a modest rise in serum potassium. Finerenone was also very well tolerated. 

Medical Research: What should clinicians and patients take away from your report?

Dr. Bakris:   Clinicians should be alerted to the fact that a novel nonsteroidal agent for blocking aldosterone exists and may be a good alternative to traditional agents once FDA approves it.

Medical Research: What recommendations do you have for future research as a result of this study?

Dr. Bakris:  Phase three clinical outcome trials with this agent need to be performed in patients with diabetic kidney disease and a separate one in patients with heart failure in order to assess long-term efficacy on outcomes in these groups already established as receiving benefit from aldosterone blockade.

Citation:

[wysija_form id=”5″]

MedicalResearch.com is not a forum for the exchange of personal medical information, advice or the promotion of self-destructive behavior (e.g., eating disorders, suicide). While you may freely discuss your troubles, you should not look to the Website for information or advice on such topics. Instead, we recommend that you talk in person with a trusted medical professional.

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

MedicalResearch.com Interview with:, & George L. Bakris MD (2015). Finerenone Reduces Urine Protein Loss in Diabetic Kidney Disease MedicalResearch.com

Last Updated on September 1, 2015 by Marie Benz MD FAAD